Glaxo, Cipla Seen as Biggest Losers as India Sets Prices

GlaxoSmithKline Plc and Cipla Ltd. may have the most to lose from a new policy in India that would limit the retail prices of drugs that generate 23 percent of the pharmaceutical industry’s revenue.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.

You might like: